SCHEMBL3560941

SCHEMBL3560941

CCOC(=O)CC(=O)c1cc(C)nc(-n2ccnc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
MITF O75030 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CD38 P28907 10/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NOS2 P35228 3/20 0.40
LMNA P02545 1/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP1A2 P05177 2/20 0.39
NOS1 P29475 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25485897 0.85 KDM4E (0.45) KDM4EMEN1MITFALDH1A1MAPT
SCHEMBL30335881 0.80 HTT (0.49) MAPTCD38NOS2CYP2C19CYP2D6
SCHEMBL25201466 0.80 HTT (0.49) MAPTCD38NOS2CYP2C19CYP2D6
SCHEMBL3558347 0.78 NOS2 (0.55) KDM4EMEN1MITFALDH1A1MAPT
SCHEMBL30261776 0.78 CD38 (0.46) MEN1KMT2ACD38TSHRMAPK1
SCHEMBL25189627 0.78 CD38 (0.46) MEN1KMT2ACD38TSHRMAPK1
SCHEMBL3559627 0.78 CD38 (0.46) CD38NOS2CYP2C19CYP1A2
SCHEMBL3566113 0.77 CD38 (0.45) CD38TSHRMAPK1NOS2CYP2C19
SCHEMBL3558150 0.76 CD38 (0.47) CD38NOS2CYP2C19CYP2D6CYP2B6
Lithium Ion SCHEMBL30723374 0.76 CD38 (0.44) CD38NOS2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
CN-101123962-A Inducible nitric oxide synthase dimerization inhibitors KALYPSYS INC (US) 2008-02-13 CN disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 KDM4E 1567/4885MEN1 4731/4885MITF 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.